Ph3 Peds VitiNCT07896434
A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline)
Timeframe: At Week 48
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 1150
Secondary (3)
Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (>= 50% Improvement in T-VASI From Baseline)
Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline)
Percentage of Participants with a Change in Baseline Cartoon Children's Dermatology Life Quality Index (CDLQI) score
Arms and interventions
Period A: Double-Blind Treatment PeriodExperimental
Pediatric participants will receive an adult-equivalent dose of upadacitinib or a matching placebo dose
Period B: Blinded Extension PeriodExperimental
Pediatric participants who complete Period A will continue into Period B and remain on blinded treatment. Pediatric participants initially randomized to blinded placebo (Period A) who have not achieved F-VASI 75 at Week 48 (nonresponders) will receive a blinded upadacitinib adult dose equivalent in Period B.
Drugs: Upadacitinib, Placebo for Upadacitinib